BioMarin Tightens Loose Rivets On Bridge To Wider PKU Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm corrects bad numbers for Kuvan new-patient starts ahead of early results with second – and maybe bigger – market player, PEG-PAL